DrugPatentWatch Database Updates: New Patent Additions
✉ Email this page to a colleague
DrugPatentWatch Database Updates: New Patent Additions
| Applicant | Tradename | Generic Name | Dosage | NDA | Number | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist Requested | Patent Expiration | Date Submitted | Usecode | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Axsome | AUVELITY | bupropion hydrochloride; dextromethorphan hydrobromide | TABLET, EXTENDED RELEASE | 215430 | 001 | Aug 18, 2022 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | 2024-05-07 | U-3419 | DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER | |||
| Novartis | FABHALTA | iptacopan hydrochloride | CAPSULE | 218276 | 001 | Dec 5, 2023 | RX | Yes | ⤷ Try a Trial | ⤷ Try a Trial | 2024-05-07 | U-3895 | TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY | |||
| Janssen Prods | EDURANT | rilpivirine hydrochloride | TABLET | 202022 | 001 | May 20, 2011 | RX | Yes | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | 2011-06-16 | U-1153 | IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION | |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Number | >Approval Date | >Type | >RLD | >Patent No. | >Product | >Substance | >Delist Requested | >Patent Expiration | >Date Submitted | >Usecode | >Patented / Exclusive Use |
